Acknowledgements

The Diabetes MILES (Management and Impact for Long-term Empowerment and Success) Study is an international collaborative established in 2011. It is led jointly by Professor Jane Speight, Foundation Director of The Australian Centre for Behavioural Research in Diabetes (ACBRD; a partnership between Diabetes Victoria and Deakin University), and Professor Frans Pouwer, of the Center of Research on Psychological and Somatic disorders (CoRPS), Tilburg University, The Netherlands.

Information about the Diabetes MILES Study international collaborative is available at www.diabetesMILES.org.

This report details the second Diabetes MILES – Australia survey (MILES-2), conducted in 2015 by the ACBRD. Diabetes MILES-2 was primarily supported and resourced by core funding provided to the ACBRD by Diabetes Victoria and Deakin University. Recruitment and data collection were supported partially by a Diabetes Australia Research Program grant. Additional support (recruitment activities and the development of the study website) was provided by Sanofi ANZ in the form of an unrestricted educational grant. None of the funding organisations were involved in the study design, data collection, or data analysis, and had no input on the preparation of this report.

The authors thank all the study participants for volunteering their time, insights and experiences. They also thank Ms Shaira Baptista for her assistance in the set-up of the online survey and associated website, and Dr Steven Trawley for technical assistance with the online survey platform and website hosting platform. The authors also thank Dr Kylie Mosely, Dr Giesje Nefs, Ms Jennifer Halliday and Dr Steven Trawley for their advice on survey content.
Diabetes is not just a metabolic condition affecting the body’s ability to convert glucose to energy. It is not just a condition that places people at risk of serious long-term physical complications. It is also a condition that places a high self-care and emotional burden on the person living with diabetes and, often, on their family members.

In 2011, the Diabetes MILES – Australia Survey Report summarised Australia’s first large-scale national survey focused on what it is like to live with and manage diabetes. Conducted by The Australian Centre for Behavioural Research in Diabetes, the survey established the unmet psychosocial needs of adults with type 1 or type 2 diabetes that had, until then, gone largely under the radar. The survey also highlighted the need for the National Diabetes Services Scheme to make mental health a priority area. This led to a four-year program of work, funded by the Australian Government, to develop resources (launched in 2016) to support people with diabetes and to enable and upskill health professionals to provide greater psychological care.

In 2015, a second large-scale, national survey of over 2,300 adults with diabetes was conducted to examine whether the same concerns as those identified in 2011 remained, and to explore emerging issues in the psychological, social and behavioural aspects of diabetes. The fact that so much of the emotional burden remains as significant as it was four years ago is a sobering reminder that we all need to do more to understand and support people with diabetes experiencing depressive and anxiety symptoms, and diabetes distress.

An important new area of inquiry highlights the social stigma experienced by many people living with diabetes, and encourages us to take greater care to ensure that our messaging around diabetes is not, in itself, stigmatising.

It is with great pleasure that I commend to you a new report: the Diabetes MILES-2 2016 Survey Report and hope that you will find it to be of great interest.

More importantly, I hope this report will give you a greater appreciation of the daily challenges faced by so many people in their efforts to live well with diabetes ‘24/7’. It is for these people, and for these reasons, that Diabetes Victoria is committed to working to reduce the impact of diabetes in the Victorian community, and to supporting such efforts at a national level. We strive to support, empower and campaign for all Victorians affected by, or at risk of, diabetes.

It is also for these reasons that, in partnership with Deakin University, Diabetes Victoria provides financial support to The Australian Centre for Behavioural Research in Diabetes – so that the Centre can continue its important research in highlighting these challenges, and to inform the work of everyone involved in the care and support of people with diabetes.

Craig Bennett
Chief Executive Officer, Diabetes Victoria
Adjunct Professor, Deakin University
# Table of Contents

- Acknowledgements ........................................................................................................... 3
- Foreword ............................................................................................................................ 4
- List of Figures ...................................................................................................................... 6
- List of Tables ....................................................................................................................... 6
- List of Abbreviations ......................................................................................................... 7
- Executive Summary ............................................................................................................ 8
- Introduction ......................................................................................................................... 10
- Method ............................................................................................................................... 12
- Respondent Characteristics ............................................................................................... 14
  - Demographics ................................................................................................................. 14
  - Clinical Characteristics .................................................................................................. 16
- Psychological and Emotional Aspects of Diabetes .......................................................... 22
  - Depressive Symptoms .................................................................................................... 22
  - Anxiety Symptoms ........................................................................................................ 22
  - Mental Health Comorbidities ....................................................................................... 24
  - Diabetes Distress ........................................................................................................... 24
  - Diabetes-Specific Quality of Life .................................................................................. 26
- Social Aspects of Diabetes ................................................................................................ 29
  - Diabetes Stigma ............................................................................................................. 29
  - Social Support ............................................................................................................... 29
  - Peer Support .................................................................................................................. 31
- Behavioural Aspects of Diabetes ...................................................................................... 32
  - Healthy Eating and Physical Activity ........................................................................... 32
  - Self-Monitoring of Blood Glucose (SMBG) .................................................................. 33
  - Diabetes Healthcare ...................................................................................................... 33
- Discussion ........................................................................................................................... 36
- References .......................................................................................................................... 42
- Appendix I: Variables included in Diabetes MILES-2 Survey ....................................... 44
- Appendix II: Scales included in Report ........................................................................... 46
List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1</td>
<td>Age (years) by diabetes type (N=2,342)</td>
<td>15</td>
</tr>
<tr>
<td>Figure 2</td>
<td>Respondents by area (N=2,336)</td>
<td>16</td>
</tr>
<tr>
<td>Figure 3</td>
<td>Diabetes-related complications by diabetes type (N=2,193)</td>
<td>17</td>
</tr>
<tr>
<td>Figure 4</td>
<td>BMI categories by diabetes type (N=1,873)</td>
<td>19</td>
</tr>
<tr>
<td>Figure 5</td>
<td>Severity of depressive symptoms by diabetes type (N=2,299)</td>
<td>22</td>
</tr>
<tr>
<td>Figure 6</td>
<td>Severity of anxiety symptoms by diabetes type (N=2,304)</td>
<td>24</td>
</tr>
<tr>
<td>Figure 7</td>
<td>Proportion of respondents with severe diabetes distress (score ≥ 40) by diabetes type (N=1,919)</td>
<td>25</td>
</tr>
<tr>
<td>Figure 8</td>
<td>Impact of diabetes profile among respondents with type 1 diabetes (N range=943–1,005)</td>
<td>26</td>
</tr>
<tr>
<td>Figure 9</td>
<td>Impact of diabetes profile among respondents with type 2 diabetes by treatment type (N range=1,029–1,183)</td>
<td>27</td>
</tr>
<tr>
<td>Figure 10</td>
<td>Participation in peer support by diabetes type (N range=1,180–2,113)</td>
<td>31</td>
</tr>
<tr>
<td>Figure 11</td>
<td>Healthful eating and physical activity over the past seven days by diabetes type</td>
<td>32</td>
</tr>
</tbody>
</table>

List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Diabetes type by gender (N=2,341)</td>
<td>14</td>
</tr>
<tr>
<td>Table 2</td>
<td>Number of respondents by state (N=2,340)</td>
<td>15</td>
</tr>
<tr>
<td>Table 3</td>
<td>Self-reported HbA1c (%) descriptive statistics (N=1,686)</td>
<td>18</td>
</tr>
<tr>
<td>Table 4</td>
<td>The top five problem areas for respondents by diabetes type</td>
<td>25</td>
</tr>
<tr>
<td>Table 5</td>
<td>The top three endorsed stigma items by diabetes type</td>
<td>29</td>
</tr>
<tr>
<td>Table 6</td>
<td>Health professionals accessed for diabetes care in the past 12 months</td>
<td>34</td>
</tr>
</tbody>
</table>
## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACBRD</td>
<td>The Australian Centre for Behavioural Research in Diabetes</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>DAWN</td>
<td>Diabetes Attitudes, Wishes and Needs study</td>
</tr>
<tr>
<td>DIDP</td>
<td>DAWN Impact of Diabetes Profile</td>
</tr>
<tr>
<td>DSAS-1/DSAS-2</td>
<td>Type 1/Type 2 Diabetes Stigma Assessment Scale</td>
</tr>
<tr>
<td>DSS</td>
<td>Diabetes Support Scale</td>
</tr>
<tr>
<td>GAD-7</td>
<td>Generalised Anxiety Disorder (7-item questionnaire)</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Glycosylated Haemoglobin (a measure of average blood glucose over 10–12 weeks)</td>
</tr>
<tr>
<td>HP</td>
<td>Health Professional</td>
</tr>
<tr>
<td>MILES</td>
<td>Management and Impact for Long-term Empowerment and Success</td>
</tr>
<tr>
<td>NDSS</td>
<td>National Diabetes Services Scheme</td>
</tr>
<tr>
<td>PAID</td>
<td>Problem Areas In Diabetes scale</td>
</tr>
<tr>
<td>PHQ-8</td>
<td>Patient Health Questionnaire (8-item questionnaire)</td>
</tr>
<tr>
<td>SMBG</td>
<td>Self-Monitoring of Blood Glucose</td>
</tr>
</tbody>
</table>
Diabetes is a serious chronic condition, affecting people of all ages, backgrounds and cultures. It requires daily self-care, and can have a significant impact on quality of life and well-being. Approximately 1.7 million Australians are currently living with diabetes, and its prevalence is increasing.\(^1\)

Diabetes MILES (Management and Impact for Long-term Empowerment and Success) – Australia\(^2,3\) was the first national survey of Australians living with type 1 or type 2 diabetes that specifically assessed the impact of diabetes on psychosocial health and well-being. Four years later, the second Diabetes MILES – Australia survey (MILES-2) was undertaken to further understand these aspects of the condition and to explore emerging issues in diabetes research and practice.

**Method**

The Diabetes MILES-2 survey was designed for Australians living with type 1 or type 2 diabetes, aged 18–75 years. English proficiency was required in order to take part.

In March 2015, an invitation to complete an online survey was posted to 20,000 National Diabetes Services Scheme (NDSS) registrants. In addition, 2,065 respondents of the 2011 MILES survey received an invitation to take part. Those who consented to take part completed the online survey, which was tailored to their diabetes type and treatment regimen.

In total, 2,342 survey respondents met the eligibility criteria.

**Respondent Characteristics**

46% of the respondents had type 1 diabetes:

- 59% women, 41% men
- Mean age: 44 ± 15 years
- Diabetes duration: 19 ± 14, range = 0–68 years
- 65% used insulin injections, 35% used an insulin pump
- 35% reported at least one diabetes-related complication
- Mean self-reported HbA1c: 7.4 ± 1.3, range = 4.0–18.1%
- 97% have had at least one hypoglycaemic event in their lifetime
- 36% were classified as overweight and 19% as obese.

54% of the respondents had type 2 diabetes:

- 43% women, 57% men
- Mean age: 61 ± 9 years
- Diabetes duration: 11 ± 7, range = 0–44 years
- 40% used oral medication, 42% used insulin
- 54% reported at least one diabetes-related complication
- Mean self-reported HbA1c: 7.1 ± 1.7, range = 4.0–20.0%
- 34% and 77% of respondents with non-insulin and insulin-treated type 2 diabetes respectively, have had at least one hypoglycaemic event in their lifetime
- 32% were classified as overweight and 53% as obese.

Respondents included adults with diabetes from all states and territories of Australia.

**Psychological and Emotional Aspects of Diabetes**

- 17% of respondents indicated that they had been diagnosed with a mental health problem, at some point in their life.
- Respondents with insulin-treated type 2 diabetes were more likely to experience moderate-to-severe symptoms of depression and anxiety, compared to other respondents
  - Moderate-to-severe depressive symptoms affected 36% of adults with insulin-treated type 2 diabetes, compared to 24% and 21% of those with type 1 and non-insulin-treated type 2 diabetes respectively
  - Moderate-to-severe anxiety symptoms affected 21% of adults with insulin-treated type 2 diabetes, compared to 16% and 13% of those with type 1 and non-insulin-treated type 2 diabetes respectively.
• Respondents with type 1 diabetes were more likely to experience severe diabetes distress, compared to other respondents
  – 24% of respondents with type 1 diabetes experienced severe diabetes distress, as compared to 20% and 11% of those with insulin-treated and non-insulin-treated type 2 diabetes respectively
  – The most commonly reported problem area for respondents (consistent across diabetes types and treatment regimens) was worrying about the future and the development of diabetes-related complications.
• Respondents with either type 1 or type 2 diabetes reported that diabetes negatively impacted their quality of life, across a number of domains. The aspects of life most commonly reported as negatively impacted by diabetes were:
  – ‘emotional well-being’, for those with type 1 diabetes
  – ‘dietary freedom’ for those with type 2 diabetes.

Social Aspects of Diabetes
• Perceived and experienced diabetes stigma was common. The most highly endorsed items were:
  – ‘Because I have type 1 diabetes, some people judge me if I eat sugary food or drinks (e.g. cakes, lollies, soft drink)’, endorsed by 67% of those with type 1 diabetes
  – ‘Because I have type 2 diabetes, some people assume I must be overweight, or have been in the past’, endorsed by 50% of those with type 2 diabetes.
• Those with insulin-treated type 2 diabetes perceived or experienced more diabetes stigma than those not using insulin.
• Respondents with non-insulin-treated type 2 diabetes perceived a higher level of social support than other respondents.
• 11% of respondents indicated that they are currently part of a peer support group or community; the majority (72%) of those had type 1 diabetes.
• 89% are not currently part of a peer support group or community and have never been in the past
  – 38% of these respondents indicated that they would like to be part of a peer support community in the future; the most preferred mode of peer support was online, regardless of diabetes type.

Behavioural Aspects of Diabetes
• Few respondents reported optimal eating and physical activity patterns. On the past seven days:
  – 25% of adults followed a healthful eating plan on all days
  – 17% of adults participated in at least 30 minutes of physical activity on all days.
• As expected, frequency of blood glucose monitoring was higher among respondents with type 1 diabetes compared to those with type 2 diabetes:
  – 55% of those with type 1 diabetes checked four to six times per day
  – 67% of those with insulin-treated type 2 diabetes checked one to three times per day
  – 92% of those with non-insulin-treated type 2 diabetes checked one to three times per day.
• The health professional relied on most was:
  – the endocrinologist, for those with type 1 diabetes (49%)
  – the general practitioner (GP), for those with type 2 diabetes (70%).
• 37% of respondents had attended a group education program for their diabetes at some point; of those, 74% regarded it as helpful or very helpful.
• Of the respondents who had never attended a group education program for their diabetes, 36% would like to attend in the future.
• 13% of respondents reported using ‘apps’ to help manage their diabetes, and majority of these were adults with type 1 diabetes.

The MILES-2 survey aimed to build on previous Diabetes MILES research, by identifying issues concerning the psychosocial well-being and unmet needs of Australians living with diabetes. The results provide a national ‘snapshot’ of the quality of life, psychosocial well-being and self-care behaviours of Australians living with type 1 or type 2 diabetes. Further analysis of these results is ongoing, and will help to inform policy and health service provision, with the ultimate aim of improving and optimising support and care for people affected by diabetes.
Diabetes is the fastest growing chronic health condition in Australia, with up to 280 new cases per day. It has been termed ‘the epidemic of the 21st century’, and is regarded as Australia’s biggest health challenge.¹

Conservative estimates suggest that approximately 1 in 20 Australian adults have diabetes.⁴ This includes the 1.2 million cases that are known and registered with the National Diabetes Services Scheme (NDSS),⁵ as well as an estimated 500,000 additional cases that remain undiagnosed or silent. Therefore, best estimates suggest that the total number of Australians with diabetes is likely closer to 1.7 million people. If diabetes continues to grow at the current rate, it is estimated that over 3 million Australians over the age of 25 will have diabetes by the year 2025.⁶

There are various types of diabetes – the most prevalent are type 1 and type 2 diabetes. While these conditions share similarities, they differ in their aetiology, management and, as this report will uncover, their psychosocial impacts.

Both types of diabetes demand a great deal of self-care and engagement, which can be challenging to maintain over time. Better understanding and acknowledgement of the psychosocial impact of living with diabetes is needed to ensure optimal care and support for people with diabetes, and to inform future health policy and service provision.

**Introduction**

**Type 1 Diabetes...**
- is an auto-immune condition in which the beta cells of the pancreas stop producing insulin
- has no cure and cannot currently be prevented
- represents approximately 10% of all cases of diabetes in Australia
- is often abrupt in its onset and has obvious symptoms
- is always managed with insulin, administered via multiple daily injections or an insulin pump.

**Type 2 Diabetes...**
- is a progressive condition in which the body becomes resistant to the effects of insulin and/or the beta cells produce insufficient or ineffective insulin
- has no cure and the exact cause is unknown; it has strong associations with lifestyle factors, genetic factors and family-related risk factors
- can be prevented through intensive lifestyle/medical management in approximately 60% of cases⁷,⁸
- represents approximately 85–90% of all cases of diabetes in Australia
- can be managed with a combination of regular physical activity and healthy eating, as well as oral and injectable medications (e.g. insulin).
The Diabetes MILES – Australia 2011 Survey

The Diabetes MILES (Management and Impact for Long-term Empowerment and Success) – Australia 2011 Survey was the first initiative of the Diabetes MILES study international collaborative, conducted by The ACBRD. The survey was completed by a large national sample (N=3,338) of Australian adults with type 1 or type 2 diabetes. The survey report provided a valuable ‘snapshot’ of the psychosocial and behavioural aspects impacting those with diabetes, and raised awareness about the unmet needs of people with diabetes. In addition to the report, many papers have been published in peer-reviewed journals, providing greater insights into the relationships between various factors influencing self-care and emotional well-being.

The Second Diabetes MILES – Australia (MILES-2) Survey

The current survey – the second Diabetes MILES, Australia Survey (MILES-2), was conducted in 2015. Four years after the original Diabetes MILES study was completed, the time was right to gain a more up-to-date snapshot of the challenges and unmet needs faced by Australians with diabetes. In addition, the MILES-2 survey enabled assessment of some new issues, e.g. diabetes stigma, memory and cognition, ‘apps’ for diabetes management and self-compassion.

This Report

This report presents a selection of findings and serves two key purposes:

- To provide an overview of the main themes and topics explored in the survey, split by diabetes type and treatment regimen where appropriate
- To make the initial results of the MILES-2 survey available to a wide audience outside of the traditional academic sphere, including health professionals, policy makers and people affected by diabetes.

Analysis of this large and rich dataset is ongoing. Further reports and publications will become available in due course. For further information, please visit www.diabetesMILES.org.
Method

Survey Design
Consistent with the aims of Diabetes MILES – Australia 2011, survey content focused on three aspects of living with diabetes:

- psychological, e.g. emotional well-being and distress
- social, e.g. diabetes stigma and peer support
- behavioural, e.g. diabetes self-management.

Survey content was grouped into eight themes:
1) Demographics, 2) My General Well-being, 3) My Feelings about Diabetes, 4) My General Health, 5) Support from Health Professionals, Family and Friends, 6) My Diabetes, 7) My Blood Glucose Levels, 8) My Thoughts and Beliefs. The survey was also tailored to diabetes type and treatment (based on information provided in the Demographics section).

A list of all the variables included in the final survey can be found in Appendix I, and information about the validated scales included in this report can be found in Appendix II. Where an appropriate measure did not exist or was not available, the research team developed items unique to the MILES-2 survey.

The MILES-2 survey was conducted primarily online, although a hard copy version was made available to those who requested it. The survey was available in English language only.

Ethics Approval
The MILES-2 survey received ethical approval from the Deakin University Human Research Ethics Committee (reference number: 2011-046).

Participant Eligibility and Recruitment
Eligible participants were adults (aged 18–75 years) living in Australia who had type 1 or type 2 diabetes, and were proficient in English.

Recruitment
Participants were recruited in several ways:

1. An invitation to complete the MILES-2 survey was posted to a random selection of 20,000 NDSS registrants with type 1 or type 2 diabetes. Only those who had previously consented to be contacted for research purposes (approximately 47%), and those who had not been invited to take part in the 2011 MILES survey (see point 2 below), were contacted. The sample was stratified according to population in each Australian state, and as follows:

- 8,000 with type 1 diabetes (40% of the total sample)
- 12,000 with type 2 diabetes (60% of the total sample); 6,000 of whom were registered as using insulin (50% of type 2 diabetes sample)

Adults with type 1 diabetes or type 2 diabetes using insulin were purposefully over-sampled to ensure adequate representation of these groups. The sample was not stratified by gender. A reminder email/letter was sent to participants three weeks after the first invitation.

2. People who had previously taken part in the 2011 survey and had consented to be contacted about future Diabetes MILES research activities (N=2,065), were emailed or posted a study invitation directly. A reminder email/letter was sent to participants three weeks after the first invitation.

3. The survey was also advertised via social media (e.g. the ACBRD and Diabetes Australia Facebook and Twitter), e-newsletters (e.g. the ACBRD Research Round-Up) and relevant publications (e.g. Diabetes Australia magazines).

Data Collection
The MILES-2 survey was hosted by Qualtrics™, a secure, online survey platform. The survey was open for participation for seven weeks (23 March–11 May 2015). As respondents progressed through the survey, their data were saved automatically by Qualtrics™.

On entry to the online survey, respondents were invited to read a plain language description of the study and indicate their consent to take part. They then completed eligibility screening and preliminary demographics questions so that a tailored version of the survey could be presented according to their diabetes type and treatment regimen.

A small sample (n=27) of respondents were unable to access the online version (due to not having access to the internet, or not knowing how to use a computer). These respondents requested a hard-copy version of the study description, consent form and survey booklet, which they completed and returned via post.
Study Sample
A total of 2,651 survey responses were recorded by Qualtrics™. However, 148 duplicate cases were identified. The main reasons for duplicate cases included participants restarting the survey after being excluded: a) due to ineligibility, b) due to losing internet connection, or c) due to survey answers not saving correctly. In cases where participants were eligible to take part, their most complete entry was retained. If there were no differences in the amount of data in each case, the first entry was retained. After duplicates were removed, 2,503 responses to the MILES-2 survey were retained. Of these, 161 respondents were excluded due to ineligibility.

The final eligible sample for the MILES-2 survey was N=2,342 respondents, and this report focuses on the findings for this sample.

Interpreting Data, Tables and Figures in this Report
All data in-text are presented as percentage (number) or mean ± standard deviation, and data in tables and graphs are presented as specified. The mean is the average response. The standard deviation is the variability in scores. A low standard deviation tells you that most people scored quite close to the mean, while a high standard deviation tells you that scores are widely spread. As mentioned, survey versions were tailored to individuals based on demographic variables (e.g. diabetes type and treatment regimen). Therefore, not all survey questions were presented to every participant. Participants could also choose to skip questions. As such, the number of people that responded to each item varies, and is not always consistent with the total number of people who took part in the MILES-2 survey. Each table and figure in this report is accompanied by an indication of the size of the sample (e.g. N=2,336) upon which the calculations are based.
Demographics

Diabetes Type

Of the 2,342 respondents, 46% (n=1,078) had type 1 diabetes and 54% (n=1,264) had type 2 diabetes. Of those who had type 2 diabetes, 42% (n=531) reported managing their diabetes with insulin.

Gender

Both men and women were well represented in the survey (Table 1). Women with type 1 diabetes were more likely to participate than men with type 1 diabetes. The reverse was true for respondents with type 2 diabetes, where men were more likely to take part. The gender distribution of those with non-insulin-treated type 2 diabetes (45% women, n=326; 55% men, n=404) and insulin-treated type 2 diabetes (40% women, n=213; 60% men, n=318) were comparable.

Age

Respondents with type 1 diabetes were, on average, younger (mean = 44 ± 15 years) than those with type 2 diabetes (mean = 61 ± 9 years). Those with insulin-treated type 2 diabetes and non-insulin-treated type 2 diabetes were of comparable ages: mean = 61 ± 89 years and 61 ± 10 years respectively (Figure 1).

Locality of Respondents

People from all states and territories took part. Approximately half (51%, n=1,181) of respondents were from New South Wales (NSW) or Victoria (VIC) (Table 2), which is representative nationally. The majority lived in metropolitan areas of Australia, although people from regional and rural areas were also represented. Respondents with type 1 and type 2 diabetes were relatively evenly split within each area (Figure 2): metropolitan (63%, n=683; 60%, n=750 respectively), regional (25%, n=272; 24%, n=303 respectively), and rural (11%, n=122; 16%, n=206 respectively).

<table>
<thead>
<tr>
<th>Gender</th>
<th>Type 1</th>
<th>Type 2</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>639 (59)</td>
<td>539 (43)</td>
<td>1,178 (50)</td>
</tr>
<tr>
<td>Men</td>
<td>436 (41)</td>
<td>722 (57)</td>
<td>1,158 (50)</td>
</tr>
<tr>
<td>Prefer not to say</td>
<td>3 (&lt;1)</td>
<td>2 (&lt;1)</td>
<td>5 (&lt;1)</td>
</tr>
<tr>
<td>Total</td>
<td>1,078 (100)</td>
<td>1,263 (100)</td>
<td>2,341 (100)</td>
</tr>
</tbody>
</table>

Note: Data are presented as n (%).

* Figures from NDSS diabetes map: www.diabetesmap.com.au
Figure 1. Age (years) by diabetes type (N=2,342)

Table 2. Number of respondents by state (N=2,340)

<table>
<thead>
<tr>
<th>State</th>
<th>Type 1</th>
<th>Type 2</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australian Capital Territory</td>
<td>54</td>
<td>132</td>
<td>186 (8)</td>
</tr>
<tr>
<td>New South Wales</td>
<td>345</td>
<td>258</td>
<td>603 (26)</td>
</tr>
<tr>
<td>Northern Territory</td>
<td>9</td>
<td>41</td>
<td>50 (2)</td>
</tr>
<tr>
<td>Queensland</td>
<td>140</td>
<td>143</td>
<td>283 (12)</td>
</tr>
<tr>
<td>South Australia</td>
<td>86</td>
<td>120</td>
<td>206 (9)</td>
</tr>
<tr>
<td>Tasmania</td>
<td>50</td>
<td>120</td>
<td>170 (7)</td>
</tr>
<tr>
<td>Victoria</td>
<td>281</td>
<td>297</td>
<td>578 (25)</td>
</tr>
<tr>
<td>Western Australia</td>
<td>113</td>
<td>151</td>
<td>264 (11)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,078</td>
<td>1,262</td>
<td>2,340 (100)</td>
</tr>
</tbody>
</table>

Note: Data are presented as n or n(%).
Marital Status
Among those with type 1 diabetes, 66% (n=706) were married or in a de facto relationship, and among those with type 2 diabetes, 71% (n=891) were married or in a de facto relationship.

Cultural Background
Around one in four respondents with type 1 diabetes (23%, n=247) indicated that they were born in a country other than Australia, compared to almost one in three respondents with type 2 diabetes (30%, n=374). Most respondents spoke English as their primary language. However, 2% (n=22) of those with type 1 diabetes and 4% (n=49) of those with type 2 diabetes mainly spoke a language other than English at home.

• 36 different languages were reported.
• Other than English, Chinese dialects were the most common languages spoken at home.

A small minority (2%, n=36) of respondents reported being of Aboriginal and/or Torres Strait Islander descent.

Membership
Around half of respondents (type 1: 55%, n=596; type 2: 44%, n=556) were a member of their local state or territory diabetes organisation (e.g. Diabetes NSW, Diabetes Victoria). Nearly all respondents with type 1 diabetes (99%, n=1,053) and type 2 diabetes (98%, n=1,222) were registered with the National Diabetes Services Scheme (NDSS).

Clinical Characteristics
Age at Diagnosis
On average, respondents with type 1 diabetes were diagnosed at 25 ± 15 years of age (range = <1–67 years). Respondents with type 2 diabetes were diagnosed much later in life than those with type 1 diabetes (mean age = 50 ± 10, range = 13–75 years). Of those with type 2 diabetes, respondents currently using insulin were diagnosed with the condition at a younger age (mean = 47 ± 10 years) as compared to those not using insulin (mean = 53 ± 10 years).

Diabetes Duration
Respondents with type 1 diabetes reported, on average, a longer diabetes duration (mean = 19 ± 14, range = <1–68 years) than respondents with type 2 diabetes (mean = 11 ± 7, range = <1–44 years).
Of those with type 2 diabetes, respondents who used insulin had a longer diabetes duration (mean = 15 ± 8 years) than those who did not use insulin (mean = 9 ± 6 years). Three per cent (n=59) had been diagnosed with diabetes less than one year ago.

**Diabetes Treatment**

Most respondents with type 1 diabetes (65%, n=698) reported managing their condition with insulin injections, on average injecting 4 ± 1 times per day. The remaining 35% (n=380) reported using an insulin pump as their main method of administering insulin.

The majority of respondents with type 2 diabetes reported managing their condition with insulin injections or blood glucose lowering tablets (42%, n=529; 40%, n=510 respectively). Of those using insulin, the average number of injections was 3 ± 1 per day. Fourteen per cent of respondents with type 2 diabetes reported managing their condition with ‘lifestyle only’ (n=176), while very small proportions of those with type 2 diabetes reported using an insulin pump, or injecting Exenatide (Byetta®).

**Diabetes-Related Complications**

A quarter of respondents (23%, n=503) had one diabetes-related complication, while 22% (n=485) reported more than one. The most common diabetes complication reported by the sample was retinopathy (18%, n=393) followed by sexual dysfunction (16%, n=356). Overall, people with insulin-treated type 2 diabetes were more likely to report diabetes-related complications than those with type 1 or non-insulin-treated type 2 diabetes (Figure 3).

**HbA1c**

Two-thirds of respondents (66%, n=1,361) reported having had a HbA1c check within the last three months, with the remainder indicating it was more than three months ago or they were unable to recall when it was last checked. This pattern was comparable across diabetes types and treatment groups, although respondents with type 1 and insulin-treated type 2 diabetes were more likely to be up-to-date with their HbA1c checks compared with those with non-insulin-treated type 2 diabetes.

Respondents were also asked to recall their most recent HbA1c value (Table 3). Around one third of respondents did not recall their most recent HbA1c. The mean HbA1c (7.3%) of the total sample indicates that, on average, respondents were within or slightly above recommended target levels (≤7%, or ≤53 mmol/mol). Of those with type 1 diabetes (57%, n=493), and insulin-treated type 2 diabetes (53%, n=197), the majority had HbA1c levels that were above recommended target levels. Around one third of those with non-insulin-treated type 2 diabetes (29%, n=132) had HbA1c levels above target.

---

**Figure 3. Diabetes-related complications by diabetes type (N=2,193)**

- **Type 1**
- **Type 2 Insulin**
- **Type 2 Non-insulin**

---

b   HbA1c is the average blood glucose over the past 10–12 weeks.

c   While an overall HbA1c target of ≤7.0% has been used here, we acknowledge that guidelines recommend individualisation of targets based on person-specific factors (e.g. age, type and duration of diabetes, medication, co-morbidities).
### Body Mass Index

Body Mass Index (BMI; see box)\(^1\) was calculated based on self-reported height and weight. On average, respondents had a BMI of 29.0 ± 6.6, and around two in three respondents were in either the overweight (34%, n=634) or obese (37%, n=388) weight range. On average, respondents with insulin-treated type 2 diabetes had a slightly higher BMI (32.8 ± 6.4) than respondents with non-insulin-treated type 2 diabetes (30.5 ± 6.6). Both were higher than those with type 1 diabetes, whose mean BMI was in the overweight range (26.5 ± 5.4) (Figure 4).

#### Hypoglycaemia

Respondents were asked about their experience of hypoglycaemia (hypo). As expected, most respondents with type 1 diabetes (97%, n=917) and insulin-treated type 2 diabetes (77%, n=361) have had at least one hypo in their lifetime. Just over a third of those with non-insulin-treated type 2 diabetes (34%, n=215) have had at least one hypo.

Over the past six months, at least one severe hypoglycaemic event\(^6\) was experienced by 17% (n=152) of respondents with type 1 diabetes, 8% (n=29) of those with insulin-treated type 2 diabetes and 5% (n=10) of those with non-insulin-treated type 2 diabetes.

Impaired awareness of hypoglycaemia was assessed using the Gold Score.\(^10\) A score of 4 or above indicates impaired awareness and often that there were limited or absent hypoglycaemia warning symptoms such as trembling, sweating, hunger and irritability.

Overall, 18% (n=419) of respondents reported impaired awareness of hypoglycaemia. Respondents with type 1 diabetes were the group most likely to have impaired awareness of hypoglycaemia (24%, n=254), followed by those with insulin-treated and non-insulin-treated type 2 diabetes (16%, n=85 and 11%, n=80 respectively).

---

\(^{6}\) A hypo that they were unable to treat themselves.
Figure 4. BMI categories by diabetes type (N=1,873)

Note: These data are self-reported and it was not possible to validate them against clinical records.
Psychological and Emotional Aspects of Diabetes

“It’s a scary thing – always hearing about how diabetes can cause serious complications – health professionals just throw these things out there to scare you into looking after yourself better, but instead it just makes me want to go more into denial about it.”

– Woman with type 1 diabetes, aged 20

“I hate having injections and at times the need for them for the rest of my life is overwhelming. There are those moments when I feel I just can’t do it anymore.”

– Man with type 2 diabetes, aged 65

Social Aspects of Diabetes

“It is depressing and confusing and doesn’t seem to have the public presence or acceptance of other diseases. It’s a fat people’s disease and it’s your own fault for being overweight.”

– Man with type 2 diabetes, aged 39

“Living with diabetes is hard, but I think the hardest part is that other people don’t understand it.”

– Woman with type 1 diabetes, aged 21

Behavioural Aspects of Diabetes

“It can be frustrating – why is my glucose high/low when I have eaten exactly the same food as I did yesterday when my levels were normal? Diabetes doesn’t seem to abide by the rules.”

– Woman with type 2 diabetes, aged 72

“Managing diabetes is tough. I worry about burning out from having to manage it full time.”

– Man with type 1 diabetes, aged 29
Respondents were asked about their current symptoms of depression and anxiety and any history of mental health problems. In addition, they were asked about their experience of diabetes-specific distress and about the impact of diabetes on their quality of life.

**Depressive Symptoms**

Depressive symptoms were measured using the eight-item Patient Health Questionnaire (PHQ-8). Respondents rated the frequency with which they had experienced symptoms of depression over the past two weeks on a scale of 0 (not at all) to 3 (nearly every day). Item scores are summed to form a total score (0 to 24). Severity of depressive symptoms was assessed using the cut-off scores of 5, 10, 15 and 20 representing mild, moderate, moderately severe and severe symptoms respectively.

On average, respondents with insulin-treated type 2 diabetes had the highest scores (7.7 ± 6.1) followed by those with type 1 (6.1 ± 5.4) and type 2 non-insulin-treated diabetes (5.6 ± 5.1).

Moderate-to-severe depressive symptoms were experienced by 36% (n=184) of respondents with insulin-treated type 2 diabetes, 24% (n=249) of those with type 1 diabetes and 21% (n=153) with non-insulin-treated type 2 diabetes (Figure 5).

**Anxiety Symptoms**

Anxiety symptoms were measured using the seven-item Generalised Anxiety Disorder scale (GAD-7). Respondents rated the frequency with which they had experienced symptoms of anxiety over the past two weeks on a scale of 0 (not at all) to 3 (nearly every day). Item scores are summed to form a total score (0 to 21). Severity of anxiety symptoms was assessed using the cut-off scores of 5, 10 and 15 representing mild, moderate and severe symptoms respectively.

On average, respondents with insulin-treated type 2 diabetes had the highest scores (5.3 ± 5.4) followed by those with type 1 diabetes (4.9 ± 5.0) and type 2 non-insulin-treated diabetes (4.0 ± 4.5).

Moderate-to-severe anxiety symptoms were experienced by 21% (n=111) of respondents with insulin-treated type 2 diabetes, 16% (n=169) of those with type 1 diabetes and 13% (n=93) with non-insulin-treated type 2 diabetes (Figure 6).
“Diabetes is a personal journey. One where you can learn a lot about yourself, your strengths, your ability to tolerate (or not) life’s challenges. One thing I’ve learned is that diabetes itself shouldn’t be disabling. With good management one can still live well and enjoy most things other people can.”

– Woman with type 2 diabetes, aged 68
Diabetes Distress

Diabetes distress involves the emotional burdens, worries and stresses associated with living with and managing diabetes.15 The Problem Areas In Diabetes (PAID) scale16 is a commonly used measure of diabetes distress, which includes 20 items, each addressing a different diabetes-related concern. Respondents indicated the extent to which each of the concerns is a problem for them on a scale of 0 (not a problem) to 4 (serious problem). Item scores are summed, and standardised to a score out of 100, with higher scores indicating greater diabetes distress.

On average, respondents with type 1 diabetes had the highest scores (25.1 ± 21.1), followed by those with type 2 insulin-treated (23.0 ± 20.7) and non-insulin-treated type 2 diabetes (15.8 ± 17.7).

The top five problem areas (i.e. the items most frequently reported as a somewhat serious or serious problem) for those with type 1 and type 2 diabetes are shown in Table 4.

Mental Health Comorbidities

A total of 17% (n=376) of respondents reported that they had been diagnosed with a mental health problem at some point in their life. This was comparable across people with type 1 diabetes (17%, n=174), insulin-treated type 2 diabetes (19%, n=94) and non-insulin-treated type 2 diabetes (16%, n=108).

Respondents were asked to indicate the mental health diagnosis, selecting from a list of six conditions (depression/depressive disorder, anxiety/anxiety disorder, bipolar disorder (I or II), schizophrenia, eating disorder, personality disorder), as well as having the option to specify ‘other’ mental health conditions not listed. They could select more than one diagnosis. Among this group, 54% (n=200) indicated that they had been diagnosed with more than one mental health problem, with the majority of respondents (41%) reporting two diagnoses, which was a consistent trend across diabetes types. Depression/depressive disorder and anxiety/anxiety disorder were the most common mental health conditions across all diabetes groups.

Figure 6. Severity of anxiety symptoms by diabetes type (N=2,304)

<table>
<thead>
<tr>
<th></th>
<th>Type 1</th>
<th>Type 2 Insulin</th>
<th>Type 2 Non-insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>No anxiety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Diabetes Distress

Diabetes distress involves the emotional burdens, worries and stresses associated with living with and managing diabetes.15 The Problem Areas In Diabetes (PAID) scale16 is a commonly used measure of diabetes distress, which includes 20 items, each addressing a different diabetes-related concern. Respondents indicated the extent to which each of the concerns is a problem for them on a scale of 0 (not a problem) to 4 (serious problem). Item scores are summed, and standardised to a score out of 100, with higher scores indicating greater diabetes distress.

On average, respondents with type 1 diabetes had the highest scores (25.1 ± 21.1), followed by those with type 2 insulin-treated (23.0 ± 20.7) and non-insulin-treated diabetes (15.8 ± 17.7).

The top five problem areas (i.e. the items most frequently reported as a somewhat serious or serious problem) for those with type 1 and type 2 diabetes are shown in Table 4.
Severe diabetes distress (PAID score of ≥40) was experienced by 24% (n=208) of respondents with type 1 diabetes, 20% (n=89) of those with insulin-treated type 2 diabetes and 11% (n=67) of adults with non-insulin-treated type 2 diabetes (Figure 7).

### Table 4. The top five problem areas for respondents by diabetes type

<table>
<thead>
<tr>
<th>Type 1 diabetes problem areas</th>
<th>N range = 895–900</th>
<th>Type 2 diabetes problem areas</th>
<th>N range = 1,059–1,064</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Worrying about the future and the possibility of serious complications</td>
<td>248 (28)</td>
<td>1. Worrying about the future and the possibility of serious complications</td>
<td>183 (17)</td>
</tr>
<tr>
<td>2. Feelings of guilt or anxiety when you get off track with your diabetes management</td>
<td>208 (23)</td>
<td>2. Feelings of guilt or anxiety when you get off track with your diabetes management</td>
<td>168 (16)</td>
</tr>
<tr>
<td>3. Feeling ‘burned-out’ by the constant effort needed to manage diabetes</td>
<td>207 (23)</td>
<td>3. Not knowing if your mood or feelings are related to your diabetes</td>
<td>127 (12)</td>
</tr>
<tr>
<td>5. Not knowing if your mood or feelings are related to your diabetes</td>
<td>151 (17)</td>
<td>5. Feeling ‘burned-out’ by the constant effort needed to manage diabetes</td>
<td>100 (9)</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as n (%).

Severe diabetes distress (PAID score of ≥40) was experienced by 24% (n=208) of respondents with type 1 diabetes, 20% (n=89) of those with insulin-treated type 2 diabetes and 11% (n=67) of adults with non-insulin-treated type 2 diabetes (Figure 7).

**Figure 7.** Proportion of respondents with severe diabetes distress (score ≥ 40) by diabetes type (N=1,919)
Diabetes-Specific Quality of Life

The impact of diabetes on quality of life was assessed using individual items from the DAWN2™ Impact of Diabetes Profile (DIDP). The DIDP is a six-item scale, with each item referring to a life domain. An additional item was added to the scale, to assess perceived impact of diabetes on dietary freedom. Respondents indicated whether diabetes has a positive impact (where 1 = very positive impact, 2 = positive impact and 3 = slightly positive impact), no impact = 4, or a negative impact (where 5 = slightly negative impact, 6 = negative impact and 7 = very negative impact) on each life domain. Respondents were also able to indicate ‘not applicable’ if the life domain was not relevant to them.

For respondents with type 1 diabetes, ‘emotional well-being’ was the aspect of life most negatively impacted by diabetes, closely followed by ‘dietary freedom’ and ‘physical health’.

Sixteen per cent (n=156) of respondents with type 1 diabetes indicated that their ‘physical health’ was, in some way, positively impacted by diabetes. ‘Relationships’ were least likely to be perceived as being negatively impacted by diabetes (Figure 8). For respondents with non-insulin-treated type 2 diabetes, ‘dietary freedom’ was the aspect of life most negatively impacted by diabetes. This was also true for those with insulin-treated type 2 diabetes, followed closely by ‘physical health’ for both groups. A substantial minority of respondents with non-insulin-treated type 2 diabetes (20%, n=134) and insulin-treated type 2 diabetes (15%, n=76) indicated that their ‘physical health’ was, in some way, positively impacted by their diabetes. ‘Relationships’, ‘work or studies’, and ‘financial situation’ were the life domains that were least likely to be perceived as being negatively impacted by diabetes (Figure 9).

Figure 8. Impact of diabetes profile among respondents with type 1 diabetes (N range = 943–1,005)
Figure 9. Impact of diabetes profile among respondents with type 2 diabetes by treatment type (N range=1,029–1,183)
“As if the disease weren’t bad enough, the stigma of type 2 diabetes is worse”

– Man with type 2 diabetes, aged 53
Respondents were asked about their social experiences of living with diabetes. This included their perceptions and experiences of diabetes-related stigma, social support and peer support.

**Diabetes Stigma**

Respondents completed questionnaires that measured perceived and experienced stigma associated with having diabetes: the Type 1 Diabetes Stigma Assessment Scale\(^1\) or the Type 2 Diabetes Stigma Assessment Scale\(^1\) (DSAS-1 and DSAS-2). The DSAS-1 and DSAS-2 are both 19-item scales designed for adults with type 1 or type 2 diabetes respectively. Respondents rated the frequency with which they had perceived or experienced stigma associated with their diabetes on a scale of 1 (strongly disagree) to 5 (strongly agree). Item scores are summed to form a total score (19 to 95), where higher scores indicate greater perceived or experienced diabetes stigma.

On average, respondents with type 1 diabetes had a score of 52.9 ± 15.6. Respondents with type 2 diabetes, on average, had a score of 40.9 ± 16.0, with those using insulin scoring slightly higher than those not using insulin (43.5 ± 16.2 and 39.0 ± 15.5 respectively). The top three endorsed items for those with type 1 and type 2 diabetes are shown in Table 5.

**Social Support**

Respondents completed a validated questionnaire and individual items about their perceived level of social support, including support from other people who also have diabetes. Social support was measured using the 12-item Diabetes Support Scale (DSS),\(^2\) Respondents indicated their level of agreement or disagreement with each item on a scale from 1 (strongly disagree) to 7 (strongly agree). A total score is calculated by taking the mean of all items, where higher scores indicate greater perceived social support.

On average, respondents with type 1 diabetes (4.4 ± 1.2) perceived they had less social support for their diabetes than those with non-insulin-treated and insulin-treated type 2 diabetes (4.7 ± 1.1 and 4.6 ± 1.1 respectively).

**Table 5. The top three endorsed stigma items by diabetes type**

<table>
<thead>
<tr>
<th>Type 1 diabetes stigma items</th>
<th>N range = 891–898</th>
<th>Type 2 diabetes stigma items</th>
<th>N range = 1,044–1,051</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Because I have type 1 diabetes, some people judge me if I eat sugary food or drinks (e.g. cakes, lollies, soft drink)</td>
<td>603 (67)</td>
<td>1. Because I have type 2 diabetes, some people assume I must be overweight, or have been in the past</td>
<td>528 (50)</td>
</tr>
<tr>
<td>2. Some people make unfair assumptions about what I can and cannot do because of my type 1 diabetes</td>
<td>602 (67)</td>
<td>2. There is a negative stigma about type 2 diabetes being a ‘lifestyle disease’</td>
<td>474 (45)</td>
</tr>
<tr>
<td>3. Some people assume that it is my fault I have type 1 diabetes (e.g. I ate too much sugar, I could have prevented it)</td>
<td>492 (55)</td>
<td>3. Because I have type 2 diabetes, some people judge me for my food choices</td>
<td>391 (37)</td>
</tr>
</tbody>
</table>

**Note:** Data are presented as n (%).
“It is much easier to talk to someone [about diabetes] who has firsthand experience”

– Man with type 1 diabetes, aged 57
**Peer Support**

**Peer Support Participation**

Respondents were asked about their participation in diabetes-related peer support activities. Eleven per cent (n=224) reported that they are currently part of a peer support group or community. The majority had type 1 diabetes (72%, n=162), with just over one quarter (28%, n=62) having type 2 diabetes. Of those who are not currently part of a peer support group or community, around one in three respondents (38%, n=718) said that they would like to be part of a peer support community in the future. This trend was consistent across all diabetes types and groups (Figure 10).

**Peer Support Preferences**

Respondents currently participating in diabetes peer support (n=224) and those wishing to participate in the future (n=718) were asked what mode of peer support they prefer. Overall, the most commonly endorsed mode of peer support was online* (71%, n=658). This was true across all diabetes types. Face-to-face group peer support was the second most preferred mode of delivery for respondents with type 1 and insulin-treated type 2 diabetes (50%, n=265 and 50%, n=94 respectively), while face-to-face with one other person was the second most preferred mode of delivery for those with non-insulin-treated type 2 diabetes (26%, n=53).

*‘Online’ refers to any internet-based peer support, including informal mediums such as Facebook groups and forums, and more organised or structured initiatives such as the ‘OzDOC’ (Australian Diabetes Online Community) tweetchat.

---

**Figure 10.** Participation in peer support by diabetes type (N range=1,180–2,113)
Respondents answered questions about the behaviours they undertake in order to manage their diabetes, including healthy eating, physical activity, monitoring blood glucose and accessing health professional support. Some of these questions were sourced from the Summary of Diabetes Self-Care Activities measure (SDSCA)\(^2\), while others were developed by the research team.

**Healthy Eating and Physical Activity**

On average, respondents reported following a healthful eating plan on 4.8 ± 2.1 of the past seven days. Around one quarter (25%, \(n=508\)) indicated that they followed a healthful eating plan on all seven days, while 8% (\(n=169\)) said that they did not follow a healthful eating plan on any of the past seven days. The number of days that respondents followed a healthful eating plan was comparable across diabetes type and treatment groups (Figure 11).

On average, respondents reported participating in at least 30 minutes of physical activity on 3.8 ± 2.2 of the past seven days. Seventeen per cent (\(n=345\)) indicated that they participated in at least 30 minutes of physical activity on all seven days, while 12% (\(n=238\)) stated that they did not participate in at least 30 minutes of physical activity on any of the past seven days. Those with type 1 diabetes or non-insulin-treated type 2 diabetes participated in physical activity on more days than those with insulin-treated type 2 diabetes (Figure 11).

Respondents were asked to indicate how important they considered following a healthy diet and regular physical activity to be for them, using the response options: not at all, somewhat, considerably and very important.

The majority of respondents (82%, \(n=1,691\)) indicated that following a healthy diet was ‘considerably’ or ‘very important’ to them. Those with type 1 diabetes and non-insulin-treated type 2 diabetes were slightly more likely to assign greater importance to diet compared to those with insulin-treated type 2 diabetes.

Likewise, undertaking regular physical activity was regarded as ‘considerably’ or ‘very important’ by most respondents (73%, \(n=1,509\)). Those with type 1 diabetes or non-insulin-treated type 2 diabetes considered regular physical activity as more important than those with insulin-treated type 2 diabetes.

**Figure 11.** Healthful eating and physical activity over the past seven days by diabetes type

- Followed a healthful eating plan (\(N=2,067\))
- Participated in at least 30 minutes of physical activity (\(N=2,070\))
Respondents were also asked to indicate how much of a burden these self-care activities are to them, using the response options: not at all, somewhat, considerable or a great burden. Following a healthy diet was regarded as a ‘considerable’ or ‘a great burden’ by 35% (n=715) of respondents. Those with insulin-treated type 2 diabetes regarded it as more of a burden than those with type 1 or non-insulin-treated type 2 diabetes.

Regular physical activity was also regarded as a ‘considerable’ or ‘a great burden’ by 35% (n=714) of respondents. Those with insulin-treated type 2 diabetes considered it as more of a burden than those with type 1 or non-insulin-treated type 2 diabetes.

**Self-Monitoring of Blood Glucose (SMBG)**

As expected, frequency of blood glucose monitoring was higher among those using insulin to manage their diabetes. Of those with type 1 diabetes who check every day, 55% (n=490) reported checking four to six times per day. By contrast, of those with insulin-treated type 2 diabetes who check daily, 11% (n=40) check five to seven times daily, with most checking one to three times per day (67%, n=242). Almost all (92%, n=223) respondents with non-insulin-treated type 2 diabetes who check every day, did so one to three times.

Nearly half of respondents with type 2 diabetes (45%, n=563) do not check their blood glucose levels daily, while this was true for only 5% (n=58) of those with type 1 diabetes. Overall, most respondents (77%, n=1,545) perceived blood glucose monitoring to be ‘considerably’ or ‘very’ important to them.

While a substantial proportion of respondents (43%, n=852) did not consider blood glucose monitoring to be a burden to them, 21% (n=421) reported that this self-care activity was ‘considerably’ or ‘a great burden’. A higher proportion of respondents with type 1 diabetes (88%, n=945) regarded blood glucose monitoring as ‘considerably’ or ‘a great burden’ compared to those with insulin-treated type 2 and non-insulin-treated type 2 diabetes (10%, n=71 and 14%, n=73 respectively).

Respondents with type 2 diabetes who monitor their blood glucose were asked if they had ever tried structured blood glucose monitoring. Around half (52%, n=543) reported that they had tried this method of monitoring, and this was more common amongst those who used insulin compared to those who did not (59%, n=270 and 47%, n=273 respectively).

**Diabetes Healthcare**

Respondents were asked about what services they have accessed for their diabetes and who they consult for their diabetes care.

**Main Health Professionals**

Respondents were asked about the health professionals they had accessed in the past 12 months for their diabetes care and who they rely on most for their diabetes care.

General Practitioners (GPs) were the most commonly accessed health professionals (91%, n=1,947) across all diabetes types (Table 6).

Those with type 2 diabetes most frequently relied upon their GP (70%, n=808) for diabetes care, while those with type 1 diabetes most frequently relied upon their endocrinologist (49%, n=481).

---

1 A method of monitoring blood glucose at set times over at least three consecutive days. It is useful for generating a pattern, which can be used to inform and monitor changes in self-care (e.g. eating patterns, physical activity, medications) in consultation with a health professional.


Table 6. Health professionals accessed for diabetes care in the past 12 months

<table>
<thead>
<tr>
<th>Health Professional</th>
<th>Type 1 n=986</th>
<th>Type 2 Insulin n=496</th>
<th>Type 2 Non-insulin n=670</th>
<th>Total sample N=2,152</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP</td>
<td>832 (84)</td>
<td>465 (94)</td>
<td>650 (97)</td>
<td>1,947 (91)</td>
</tr>
<tr>
<td>Endocrinologist</td>
<td>738 (75)</td>
<td>219 (44)</td>
<td>100 (15)</td>
<td>1,057 (49)</td>
</tr>
<tr>
<td>Diabetes educator</td>
<td>531 (54)</td>
<td>211 (43)</td>
<td>190 (28)</td>
<td>932 (43)</td>
</tr>
<tr>
<td>Dietitian/nutritionist</td>
<td>284 (29)</td>
<td>130 (26)</td>
<td>160 (24)</td>
<td>574 (27)</td>
</tr>
<tr>
<td>Optometrist/ophthalmologist</td>
<td>757 (77)</td>
<td>383 (77)</td>
<td>471 (70)</td>
<td>1,611 (75)</td>
</tr>
<tr>
<td>Podiatrist</td>
<td>405 (41)</td>
<td>272 (55)</td>
<td>347 (52)</td>
<td>1,024 (48)</td>
</tr>
<tr>
<td>Mental health professional</td>
<td>132 (13)</td>
<td>50 (10)</td>
<td>52 (8)</td>
<td>234 (11)</td>
</tr>
</tbody>
</table>

Note: Data are presented as n (%).

Group Education

Over one third of respondents (37%, n=802) had previously attended group education for their diabetes; slightly higher among respondents with type 1 diabetes (40%, n=399) compared to those with insulin-treated or non-insulin-treated type 2 diabetes (35%, n=174; 34%, n=229 respectively). Of those who had never attended group education, over one third (36%, n=482) indicated that they would like to in the future. Again, a slightly higher proportion of these respondents had type 1 diabetes (41%, n=243) than insulin-treated type 2 diabetes (34%, n=105) or non-insulin-treated type 2 diabetes (31%, n=134).

Overall, most respondents (74%, n=587) that had attended group education regarded it to be ‘helpful’ or ‘very helpful’. This was a consistent trend across diabetes types.

‘App’ Use

Respondents were asked about their use of mobile technology in the management of their diabetes, specifically their use of smartphone or tablet applications (‘apps’). Most respondents (87%, n=1,783) indicated that they do not use apps for the management of their diabetes. The main reason for this (35%, n=627) was that they did not think that apps could help them manage their diabetes. This was consistent across all diabetes types.

A higher proportion of respondents with type 1 diabetes (20%, n=193) used apps compared with those with insulin-treated or non-insulin-treated type 2 diabetes (6%, n=27; 7%, n=41 respectively). Those with type 1 diabetes were most likely to use apps for carbohydrate counting (74%, n=143), while respondents with type 2 diabetes were most likely to use apps for recording blood glucose levels (60%, n=43).
“It would be great to see psychologists/psychiatrists included in type 1 diabetes treatment.”

– Woman with type 1 diabetes, aged 28
Discussion

The second Diabetes MILES – Australia survey (MILES-2) was completed by more than 2,300 Australian adults with type 1 or type 2 diabetes. The strong emphasis on the experience of the person living with diabetes, as opposed to diabetes itself, means this survey’s findings provide an important snapshot of the psychological, social and behavioural challenges faced by this group nationally, and highlight unmet needs and priority areas for support.

The current study builds on the previous Diabetes MILES study initiatives to deliver Australia’s second large-scale assessment of the psychosocial aspects of type 1 and type 2 diabetes, and to introduce novel topics of investigation at a population level.

Similar to the MILES 2011 survey, the MILES-2 survey found that adults with type 1 and type 2 diabetes have different response profiles across various domains, and that the response profiles of adults with type 2 diabetes also differ according to treatment type (i.e. insulin and non-insulin). This suggests that unique concerns and unmet needs exist for each group. Thus, the MILES-2 findings are discussed here by diabetes type and treatment.

Respondents with Type 1 Diabetes

Survey respondents with type 1 diabetes made up 46% of the total sample, with more women (59%) taking part than men. Unsurprisingly, those with type 1 diabetes were, on average, younger compared to those with type 2 diabetes, and had lived with the condition for a longer period of time. Despite having lived with diabetes for longer, respondents with type 1 diabetes had the fewest diabetes-related complications of all groups (i.e. compared to respondents with non-insulin-treated and insulin-treated type 2 diabetes). On average, their self-reported HbA1c (mean of 7.4%, or 57.4 mmol/mol) was only slightly above the recommended target range. From a physical point of view, respondents with type 1 diabetes appeared to be managing their health well, as compared to the other groups: they had the lowest BMI of all diabetes types/treatment groups, and were engaging in healthy eating and regular physical activity more frequently than those with type 2 diabetes.

Respondents with type 1 diabetes had higher diabetes distress than those with type 2 diabetes, and they regarded their ‘emotional well-being’ as the aspect of life most negatively impacted by their condition. This suggests that, for some, the relatively successful management of their physical health may be achieved at the expense of their emotional and social well-being.

Those with type 1 diabetes also reported the lowest levels of perceived social support of all groups, and many respondents perceived and experienced diabetes stigma. Interestingly, those with type 1 diabetes were the most likely to engage in peer support for their diabetes, which may be a reflection of their perceived lack of social resources or a perception that living with type 1 diabetes can only really be understood by others who also live with the condition.

Respondents with Type 2 Diabetes using Insulin

Respondents with insulin-treated type 2 diabetes were the oldest group (mean age > 60 years) and made up 23% of the total sample, with more men (60%) taking part than women. The response profile of these respondents appears to be aligned more closely, in many respects, to those with type 1 diabetes than their non-insulin-treated counterparts with type 2 diabetes.

Overall, the self-reported health and psychosocial outcomes of these respondents appeared to be worse than it was among the other groups. This may be reflective of the challenges associated with the older age of this group, and the increased likelihood that they have co-morbid health conditions or concerns unrelated to their diabetes. Coping with the progressive nature of their diabetes, in addition to other health concerns, may contribute to the burden they experience. These respondents experienced increased challenges with their health, reporting the highest number of diabetes-related complications and the highest BMI of all groups. Though the difference was only marginal, they also had a higher HbA1c (mean of 7.5%, or 58.5 mmol/mol) compared to other groups. Furthermore, these respondents engaged in healthy eating and physical activity less frequently, and regarded these self-care activities as less important than other groups. Health professionals must remain aware of the unique needs of this group, who may require additional resources, such as psychosocial support or information, in order to fully engage with their diabetes. This is particularly important as the condition progresses.

On average, adults with insulin-treated type 2 diabetes had the most severe depressive and anxiety symptoms, and were the most likely to self-report current or past diagnosis of a mental health condition. ‘Dietary freedom’ was the aspect of life most negatively impacted by their diabetes. While those with type 1 diabetes had the highest diabetes distress scores, respondents with
“Even though my diagnosis was a shock and upsetting to me, I feel as though it was a wake-up call for me to take stock and look after myself. I am now looking towards a healthier future and a longer life. So, in some ways my diabetes has given me a new lease on life.”

– Woman with type 2 diabetes, aged 45
insulin-treated type 2 diabetes closely followed, with scores more similar to those with type 1 diabetes than non-insulin-treated type 2 diabetes. This pattern of responses was also evident in regard to levels of perceived social support. Furthermore, those with insulin-treated type 2 diabetes perceived and experienced more diabetes-related stigma than those with non-insulin-treated type 2 diabetes.

Respondents with Type 2 Diabetes not using Insulin

Survey respondents with non-insulin-treated type 2 diabetes made up 31% of the total sample with more men (55%) than women taking part. The response profile of those with non-insulin-treated type 2 diabetes was very different from those with type 1 or insulin-treated type 2 diabetes, possibly because of the way in which their diabetes was managed; 70% used blood glucose lowering tablets as their primary treatment, while 24% used lifestyle modifications.

Though they had a slightly higher level of diabetes-related complications, and, on average, a higher BMI than respondents with type 1 diabetes, their average HbA1c (mean of 6.8%, or 50.8 mmol/mol) was lower than both other groups, and within the recommended target range.9

From a psychosocial perspective, respondents with non-insulin-treated type 2 diabetes were faring better than other groups. They had the lowest levels of depressive and anxiety symptoms, and least diabetes distress of all groups. They also perceived and experienced somewhat less diabetes-related stigma compared to the insulin-treated type 2 group, and reported the highest perceived social support. Like those with insulin-treated type 2 diabetes, when asked which aspect of life was most negatively impaired by their diabetes, they indicated it was their ‘dietary freedom’. While these respondents experienced fewer physical and psychosocial problems than both other groups, many of the respondents with type 2 non-insulin-treated diabetes still exhibited sub-optimal psychological, social and behavioural outcomes. It is important to remain aware that, as their diabetes progresses over time, changes in their diabetes self-management (e.g. more tablets, starting insulin) is likely to impose new challenges for these adults with type 2 diabetes. Therefore, it is necessary to monitor both the physical and psychosocial well-being of this group as their diabetes progresses. Regular screening of emotional health issues is one way to prevent the onset of more serious problems, such as diabetes burnout.

Comparison of Findings from the MILES 2011 and 2015 Surveys

The first (2011) and second (2015) Diabetes MILES – Australia national survey studies were conducted four years apart, and thus provide two comparable ‘snapshots’ of the psychological, social and behavioural aspects of living with type 1 or type 2 diabetes in Australia. While the first Diabetes MILES – Australia findings were widely disseminated (e.g. through reports and publications, conference presentations, symposia, health professional training and talks at consumer events), many of the psychosocial issues and unmet needs identified in the 2011 survey appear to remain.

The MILES-2 findings are strikingly consistent with the results of the first Diabetes MILES – Australia survey. For example, emotional well-being remains a prominent issue for people with diabetes, and a substantial minority experience clinically relevant psychological problems. Approximately one in five respondents experienced severe diabetes distress, and a quarter experienced moderate-to-severe depressive symptoms; rates that are very similar to those found in 2011. Despite these high rates, only 8% of MILES 2011 respondents and 11% of MILES-2 respondents indicated that they had accessed a mental health professional in the past 12 months to help with their diabetes. Whilst there has been a slight increase in mental health professional access between surveys, these rates are still low. This may be reflective of the healthcare priorities of Australians living with diabetes, or the lack of mental health professionals (especially those with expertise in diabetes) in Australian healthcare settings. Thus, ensuring that people with diabetes have appropriate emotional and mental health support – from their diabetes and general health professionals – remains a national priority. Indeed, this has been recognised as a priority area in the new Australian National Diabetes Strategy 2016–2020.22 Routine monitoring of emotional and mental health issues and ensuring these are addressed appropriately (by diabetes health professionals or referral as needed to mental health specialists) are integral to optimising diabetes care. A new NDSS handbook for health professionals23 provides practical resources to enable health professionals to support the emotional and mental health needs of people with diabetes.

In addition to the psychological unmet needs of people with diabetes, the MILES-2 survey revealed that Australian adults with diabetes face social challenges, again consistent with the 2011 survey results. Many respondents perceived a lack of social support around their diabetes self-management and coping.
Furthermore, only one in ten were participating in peer support programs/initiatives – the same rate of participation observed in 2011. More efforts are required to promote existing peer support communities, and engage people with these groups, particularly online-based communities, as many people with diabetes have a preference for this mode of delivery. Online peer support may also remove barriers to access for those who, as shown in the current study, perceive or experience stigma associated with their diabetes. Health professionals are encouraged to be mindful of the social impacts of diabetes (e.g. stigma) when making referrals to peer support groups. People who experience diabetes stigma may be more vulnerable in social situations where they may fear being negatively judged or blamed for having diabetes. Therefore it is important to respond appropriately to the unique needs of each person. Health professionals are also encouraged to be aware of the various peer support initiatives that exist in their areas, including those that are online, so that they can readily refer them to people when appropriate.

The self-management behaviours and physical health outcomes of MILES-2 respondents are also comparable to the 2011 survey participants. Across the board, adults with type 1 and type 2 diabetes have difficulties in engaging in healthy eating or physical activity as recommended. It is important to note that this is also true of the general Australian population. However, people with diabetes have an even greater imperative to engage in these healthy behaviours, as they form part of an optimal self-management regimen for the prevention or delay of diabetes-related complications. Health professionals need to continue helping people with diabetes address the barriers to healthy lifestyle habits. This includes providing information about what constitutes a healthy lifestyle in a non-judgemental and non-threatening way, working collaboratively to set achievable goals, and follow-up on these goals, or making referrals (as needed) to appropriate health care providers, e.g. diabetes educators, dietitians or exercise physiologists.

Structured diabetes education is also an important consideration within the clinical context. In both the MILES and MILES-2 surveys, approximately half the respondents had never been offered structured group education, despite international guidelines recommendations specifying otherwise. Evidently, little progress has been made in the time between these surveys to increase healthcare professional referrals to structured/group education. A recent review identified that health professionals do not routinely recommend structured education, with some being unenthusiastic about this approach or even being discouraging about its usefulness. Health professionals need to fully support structured education as it is an evidence-based approach to improving diabetes management. Health professionals and people with diabetes may need greater awareness of the relevance of such programs, where they are available (in metropolitan, regional and rural areas), how such programs can be accessed (e.g. online, face-to-face), and what these programs involve.

Overall, the findings of the Diabetes MILES and MILES-2 surveys are comparable, suggesting that the unmet needs identified in 2011 are still prominent issues today that require further attention and consideration. Some respondents completed both the 2011 and 2015 surveys, though we have not been able to report on this sub-sample here. Using this longitudinal dataset will enable us to explore what changes, if any, have occurred over the past four years, and the reasons for any changes. These results will be important for determining what may have been effective at producing positive changes to people with diabetes.

Self-reported health and psychological outcomes in MILES-2 do not appear to differ much from the findings of the first MILES survey in 2011. However, it is reasonable to expect that effecting change in psychological, social and behavioural aspects of living with diabetes will take both time and the support of health professionals, with prioritisation of the holistic needs of people with diabetes.

**Strengths and Limitations**

The survey methods used were successful in generating a diverse sample: gender balance, a wide age range, a variety of ethnicities and socio-economic backgrounds, and a mix of people living in metropolitan, regional and rural areas in all states and territories of Australia. Relative to the stratification method used, those with type 1 diabetes were slightly over-represented in the sample, which may reflect a generally higher level of engagement in diabetes-related research in this group. Those with type 1 diabetes using an insulin pump were over-represented (35%) in the sample, but this was not due to intentional over-sampling. Pump users may be more engaged in research because they perceive themselves to benefit from advances in knowledge, or it may be reflective of the fact that pump users tend to be more highly educated and from higher socio-economic backgrounds (and therefore more likely to engage in research), relative to non-pump users.29
“Thank you for the opportunity to take part in this survey. Living with diabetes is a complex journey.”

Man with type 2 diabetes, aged 53
Amongst respondents with type 2 diabetes, 42% were using insulin which is almost double the proportion observed on the NDSS database (24%), but less than intended given the purposeful sampling stratification (50%). Based on our previous research, Australian adults with type 2 diabetes who use insulin (compared with those not using insulin) have a longer diabetes duration, are more likely to have at least one diabetes-related complication, and are more likely to have depressive and anxiety symptoms. These factors may make them less likely to engage in research.

All study respondents were asked to self-report their most recent HbA1c level. Whilst this is a common, non-invasive method of obtaining glycaemic outcome data in research, people with diabetes tend to either forget or inaccurately report the data. This has implications for research exploring how HbA1c relates to other areas of life (e.g. emotional health), as well as having implications within the clinical context.

The survey was offered only in English, thus limiting participation among those Australians who do not feel confident to complete a survey in English. Compared with the general population in Australia, the current sample was more likely to speak English as their main language, to be married or in a de facto relationship, to be in paid employment, and have qualifications beyond high school level. This suggests that those who took part are relatively advantaged, and are likely to have more social resources, better health literacy and greater access to health services than Australians with diabetes generally. A very small proportion of respondents identified as being of Aboriginal and Torres Strait Islander (ATSI) heritage, suggesting that this population was not well represented in the current study and that other means are needed to identify the impact of diabetes on their emotional well-being and related outcomes.

The MILES-2 sample size (N=2,342) was notably smaller than the 2011 sample (N=3,338), and there are a number of possible explanations for this. Firstly, the online format of the survey may have been a barrier for some people who may not be confident in using (or have access to) a computer or tablet device, or the internet. Secondly, NDSS registrants were contacted frequently with invitations to participate in research during late 2014 and early 2015, and therefore may have been experiencing research fatigue (i.e. when the target population feels bombarded and ceases/reduces engagement with research activities). Lastly, online surveys in general are increasingly common, and decreasing response rates have been observed elsewhere.

Therefore, the smaller sample size in MILES-2 may simply be a reflection of a broader issue with online research.

Despite these limitations, the MILES-2 survey was an economical approach to surveying a wide range of Australian adults with diabetes within a relatively short time-frame. The qualitative feedback from respondents (see page 21) indicated that the survey was well received, with topics being relevant, and the experience of taking part being helpful for clarifying their thoughts and feelings about their diabetes. Overall, MILES-2 is a success, based on the large sample size, cost-effective survey methods, and the breadth and depth of the findings.

**Future Directions**

Analysis of MILES-2 results is ongoing, and like the 2011 MILES survey, the findings will be widely disseminated through national and international conferences, peer-review publications and consumer forums.

It was beyond the remit of this report to conduct longitudinal analyses using data of those who participated in both the 2011 and 2015 surveys. However, we do plan to explore the predictors and consequences of psychological distress and sub-optimal behavioural diabetes management in a non-clinical, population-based sample across the two time-points. This will be the first study of its kind in Australia that will attempt to track the natural trajectory of psychosocial problems in people with diabetes and to investigate any social, economic and/or demographic factors that may contribute to differences in psychosocial experiences.

It is our intention to conduct further surveys in the future to continue to follow all respondents who have indicated willingness to continue their participation in MILES studies. This will enable us to build on the existing longitudinal dataset using a third wave of data collection, and to increase the sample size and breadth of survey topics available in the longitudinal sample.

**Conclusions**

The MILES-2 study builds on the previous Diabetes MILES initiatives, providing new knowledge and novel insights into the experience of living with type 1 or type 2 diabetes among Australian adults. The depth and breadth of the data available in this large sample raises further awareness of the psychosocial impact of living with diabetes, highlights continuing unmet needs and priority areas for future investigation, and may be used to inform health policy, clinical practice, program and intervention development, and evaluation.


## Appendix I: Variables included in Diabetes MILES-2 Survey

<table>
<thead>
<tr>
<th>Concept/topic</th>
<th>Measure or variable</th>
<th>Diabetes type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td><strong>Eligibility screen</strong></td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Diabetes type, age, live in Australia</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Demographic and socio-economic details</strong></td>
<td>Gender, state, postcode, country of birth, language, marital status, living situation, income, employment, education</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Diabetes details</strong></td>
<td>Diabetes duration, diabetes treatment</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Diabetes organisation membership, how they heard about survey</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>My General Well-being</strong></td>
<td><strong>General emotional well-being</strong></td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>World Health Organisation Well-being Index (WHO-5)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>General life satisfaction (single item)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Depressive symptoms</strong></td>
<td>Patient Health Questionnaire (PHQ-8)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Anxiety symptoms</strong></td>
<td>Generalised Anxiety Disorder scale (GAD-7)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>My Feelings about Diabetes</strong></td>
<td><strong>Diabetes-specific distress</strong></td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Problem Areas In Diabetes Scale (PAID)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Diabetes Distress Scale (DDS)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Type 1 Diabetes Distress Scale (T1-DDS)</td>
<td>T1</td>
</tr>
<tr>
<td><strong>Diabetes-related and generic stigma</strong></td>
<td>Type 1 Diabetes Stigma Assessment Scale (DSAS-1)</td>
<td>T1</td>
</tr>
<tr>
<td></td>
<td>Type 2 Diabetes Stigma Assessment Scale (DSAS-2)</td>
<td>T2</td>
</tr>
<tr>
<td></td>
<td>Stigma Scale for Chronic Illnesses – 8 item version</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>6 study-specific items about portrayal of diabetes in the media</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Quality of life</strong></td>
<td>DAWN Impact of Diabetes Profile (DIDP)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Illness centrality</strong></td>
<td>Centrality Scale</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>My General Health</strong></td>
<td><strong>Health background</strong></td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Physical and mental health comorbidities and complications, height and weight, smoking status, health insurance and pension</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Weight stigma</strong></td>
<td>Weight Self-Stigma Questionnaire (WSSQ)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Memory</strong></td>
<td>Prospective and Retrospective Memory Questionnaire (PRMQ)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Support from Health Professionals, Family and Friends</strong></td>
<td><strong>Healthcare</strong></td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Access to providers in last 12 months, main provider, group structured education</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Social support</strong></td>
<td>Diabetes Support Scale (DSS)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Social Support subscale of Diabetes Care Profile (DCP)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Peer support</strong></td>
<td>Study-specific items</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>My Diabetes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Self-care</strong></td>
<td>Diet and physical activity subscales of the Summary of Diabetes Self-Care Activities (SDSCA)(^{21})</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study-specific items: dietary behaviours</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Study-specific items: physical activity behaviours</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Study-specific items: blood glucose monitoring</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td></td>
<td>Modified Importance and Burden items (for diet, physical activity, blood glucose monitoring) from the Summary of Diabetes Self-Care Inventory – Revised (unpublished)</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Diabetes treatment</strong></td>
<td>Study-specific items assessing frequency/time of day for injections/bolusing, frequency of forgetting and skipping injections/bolus/medication dose, reasons for forgetting/skipping</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>HbA1c</strong></td>
<td>Study-specific items</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>App use for self-management support</strong></td>
<td>Study-specific items</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Diabetes-specific self-efficacy</strong></td>
<td>Confidence In Diabetes Self-Care (CIDS) (insulin-using)(^{44}) and non-insulin using versions(^{45})</td>
<td>T1 &amp; T2</td>
</tr>
<tr>
<td><strong>Psychological insulin resistance</strong></td>
<td>Insulin Treatment Appraisal Scale (ITAS)(^{46})</td>
<td>T2</td>
</tr>
<tr>
<td></td>
<td>‘Willingness to begin insulin’ single item(^{47})</td>
<td>T2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>My Blood Glucose Levels</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyperglycaemia</strong></td>
</tr>
<tr>
<td><strong>Hypoglycaemia</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>My Thoughts and Beliefs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Self-esteem</strong></td>
</tr>
<tr>
<td><strong>Self-compassion</strong></td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
</tbody>
</table>

**Note:** The MILES-2 survey was tailored to diabetes type/treatment. Therefore, not all variables were administered to all respondents.
## Appendix II: Scales Included in Report

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DAWN2™ Impact of Diabetes Profile (DIDP)</strong>&lt;sup&gt;17&lt;/sup&gt;</td>
<td>The six-item scale measures diabetes-specific quality of life, with each item referring to a life domain associated with diabetes. Respondents are asked to indicate the perceived level of impact of the life domain on a 7-point scale (1 = A very positive impact; 4 = No impact; 7 = A very negative impact). Respondents are also given the option to indicate ‘not applicable’. Items can be examined individually, or by producing a composite score.</td>
</tr>
<tr>
<td><strong>Diabetes Support Scale (DSS)</strong>&lt;sup&gt;20&lt;/sup&gt;</td>
<td>The 12-item scale measures perceived social support for diabetes. Respondents are asked to indicate their level of agreement or disagreement with each item on a 7-point scale (1= Strongly disagree; 7 = Strongly agree). A total score is formed by taking a mean of all items, with higher scores indicating greater perceived social support.</td>
</tr>
<tr>
<td><strong>Generalized Anxiety Disorder scale (GAD–7)</strong>&lt;sup&gt;14&lt;/sup&gt;</td>
<td>The 7-item scale assesses the presence and severity of seven key anxiety symptoms. Respondents rate the frequency with which they have experienced symptoms of anxiety over the past two weeks on a 4-point scale (0 = Not at all; 3 = Nearly every day). Item scores are summed to form a total score out of 21. Scores of 5, 10 and 15 represent cut-points for mild, moderate, and severe anxiety symptoms, respectively.</td>
</tr>
<tr>
<td><strong>Gold Score</strong>&lt;sup&gt;10&lt;/sup&gt;</td>
<td>The single item Gold Score measures hypoglycaemia awareness. The Gold Score asks respondents: “Do you know when your hypos are commencing?” Responses are on a 7-point scale (1 = Always aware; 7 = Never aware). A score of ≥ 4 implies impaired awareness of hypoglycaemia.</td>
</tr>
<tr>
<td><strong>Patient Health Questionnaire – 8 item version (PHQ–8)</strong>&lt;sup&gt;12&lt;/sup&gt;</td>
<td>The 8-item scale assesses the presence and severity of eight key depression symptoms. Respondents rate the frequency with which they have experienced symptoms of depression over the past two weeks on a 4-point scale (0 = Not at all; 3 = Nearly every day). Item scores are summed to form a total score out of 24. Scores of 5, 10, 15 and 20 represent cut-points for mild, moderate, moderately severe and severe depressive symptoms, respectively.</td>
</tr>
<tr>
<td><strong>Problem Areas In Diabetes scale (PAID)</strong>&lt;sup&gt;16&lt;/sup&gt;</td>
<td>The 20-item scale measures diabetes distress, defined as distress resulting from diabetes and its management. Each item addresses a different concern or issue associated with diabetes. The extent to which each of these potential concerns is a problem is rated on a 5-point scale (0 = Not a problem; 4 = Serious problem). Item scores are summed, and standardised to a score out of 100. Scores ≥ 40 indicate severe diabetes distress.</td>
</tr>
<tr>
<td><strong>Type 1/Type 2 Diabetes Stigma Assessment Scale</strong>&lt;sup&gt;18,19&lt;/sup&gt; (DSAS-1 and DSAS-2)</td>
<td>The 19-item scales measure perceived and experienced stigma associated with living with either type 1 or type 2 diabetes. Both measures contain three subscales. On a 5-point scale (1 = Strongly disagree; 5 = Strongly agree), respondents rate the extent to which they agree with each statement. Item scores are summed to form a total score (19 to 95), where higher scores indicate greater perceived or experienced diabetes stigma. Subscale scores are also obtained by taking the sum of all items within the subscale.</td>
</tr>
</tbody>
</table>